2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiol
about
sameAs
Diagnostic Strategies for Early Recognition of Cancer Therapeutics-Related Cardiac Dysfunction.Two-dimensional strain echocardiography for detection of cardiotoxicity in breast cancer patients undergoing chemotherapy.Anthracycline Chemotherapy and Cardiotoxicity.Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients.Cardiac Imaging: Multimodality Advances and Surveillance Strategies in Detection of Cardiotoxicity.Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts.Cardio-oncology: cardiovascular complications of cancer therapy.The role of cardiac MRI in cardio-oncology.Echocardiographic reference ranges for normal left ventricular 2D strain: results from the EACVI NORRE study.The Role of Biomarkers in Detection of Cardio-toxicity.Cardiac safety of systemic therapy in breast cancer patients with high risk of atherosclerosis complications.2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility.Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy.Myocardial strain to detect subtle left ventricular systolic dysfunction.Cardio-Oncology: Progress in Diagnosis and Treatment of Cardiac Dysfunction.The influence of chemotherapy on the right ventricle: did we forget something?Integrated cardiovascular safety: multifaceted considerations in drug development and therapeutic use.Role of Imaging in Cardio-Oncology.Breast cancer treatment-induced cardiotoxicity.Echocardiographic evaluation of cardiac function after cancer chemotherapy.Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology.[Overweight and obesity are risk factors for development of cardiotoxicity from anthracyclines or sequential administration of anthracyclines and trastuzumab].ANMCO/AIOM/AICO Consensus Document on clinical and management pathways of cardio-oncology: executive summaryDeveloping a Comprehensive Cardio-Oncology Program at a Cancer Institute: The Moffitt Cancer Center Experience.Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance.Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies.Cancer and Thrombotic Risk: The Platelet Paradigm.Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1.Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2.Molecular targeted treatment of metastatic colorectal cancer: the cardiovascular adverse effects of Bevacizumab and Cetuximab.Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study.Clinical feasibility and validation of 3D principal strain analysis from cine MRI: comparison to 2D strain by MRI and 3D speckle tracking echocardiography.Chemotherapy and echocardiographic indices in patients with non-Hodgkin lymphoma: the ONCO-ECHO study.The paradox of the first cycle of chemotherapy-transient improvement of contractility and diastolic function after the first cycle of anthracycline-based chemotherapy: a prospective clinical trial.Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience.Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of General Medicine (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), SpanPharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients.Long-Term and Latent Side Effects of Specific Cancer Types.Approach to cardio-oncologic patients with special focus on patients with cardiac implantable electronic devices planned for radiotherapy: results of the European Heart Rhythm Association survey.Statins and cancer survivors: the need for structured guidelines.
P2860
Q33565936-6448F84F-DB71-4130-8E7A-8A6328D1258CQ33565936-C3D91983-1DA6-465E-9F33-D07114236EA0Q33593674-107ECA6E-B696-442F-9133-866B9C0862CCQ33593674-FD89FA83-BB8E-475C-A12D-AFDF30FF963EQ37694541-216CFF8E-D941-4081-B522-5C53DBB3CBDCQ37694541-E28D03C6-6F16-418B-9D36-F0E4247ED44BQ38371293-AB7E7C4B-5820-4963-B751-CECFFEFA1617Q38371293-E86432AB-6FDA-4300-975C-B23304B9DA93Q38632789-B3C4EEEC-7E93-457A-8503-2C682475540FQ38657849-201218F5-2583-4A50-ABEA-158C50E52ED3Q38665281-2A54D7DB-C672-476A-A1D4-B62C9D9852CAQ38668133-E18F5844-69EB-4CA7-904B-039882696FF6Q38715356-51E674B9-DC67-4F25-A1B5-CFFDC356AD5BQ38728535-2E056160-EF04-48F5-806A-896E628A6B66Q38804715-80D28491-39E1-445E-B862-3672F46880B9Q38853230-AA61176E-C00B-4FAF-941B-38806BD11BE6Q39018351-92607073-A302-40D7-A1C3-97CBE8646E2DQ39021835-8E867248-35DF-4F6C-8FCB-2D7F9FBBDE46Q39078275-D62EF621-5C1C-4183-AFF5-E7835B2522B5Q39133246-10D4D265-EA65-4519-A5E5-10BFCD4400E8Q39164190-01152329-2D8A-4245-B9CE-C625BD4845C0Q39285218-3E7AB78A-D83D-4C18-BE55-3E8AEF398E4AQ39428826-D8811C03-98E7-46E4-92D9-83C94865BCF1Q39429845-631B2FB3-827A-451D-8B9B-8D763DAA9D42Q40108112-03ED86AB-2082-4A5A-8C2E-CD3C41AF4229Q40108112-792D0B31-FDCE-432E-B4A5-969887CD69B3Q40365766-C66C6E02-EE79-48B9-964D-009569F561D5Q41082970-64D60A39-C1F4-427C-A2CE-FC9E5A81C671Q41082970-7C4FF85B-107C-42C1-ACAF-C47A414F8823Q41098209-4C0E828C-8973-4CBD-9B4C-E5BA79D3614FQ41098209-AE65CA97-087F-4F47-8D20-28F631714B7FQ41348012-80CA4D23-F75A-4A2A-899E-F926FA816543Q41348012-F93A9FDF-0D4E-4AD6-B8A4-DD4DD949509CQ42373758-06764023-8276-4723-8056-ACBFCBE4AA3EQ42373758-FAE5D5BF-200D-4B85-A9D0-013117FDE1F0Q44264785-435C6E38-B5FC-41E2-A100-CB2E43099D7AQ44264785-461DF25A-2204-4EB9-9F07-9718CBD56AC3Q45073135-A4E2438A-C0D1-465C-A5E1-06B86FE93520Q45073135-DA314BD5-ED3D-4A7A-A2BC-3D0AFC79016AQ45073137-4C71EAFF-FE84-4B9A-9EAA-290CE393AC79
P2860
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiol
description
article
@en
im September 2016 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2016
@uk
name
2016 ESC Position Paper on can ...... he European Society of Cardiol
@en
2016 ESC Position Paper on can ...... he European Society of Cardiol
@nl
type
label
2016 ESC Position Paper on can ...... he European Society of Cardiol
@en
2016 ESC Position Paper on can ...... he European Society of Cardiol
@nl
altLabel
2016 ESC Position Paper on can ...... mittee for Practice Guidelines
@en
2016 ESC Position Paper on can ...... mittee for Practice Guidelines
@nl
prefLabel
2016 ESC Position Paper on can ...... he European Society of Cardiol
@en
2016 ESC Position Paper on can ...... he European Society of Cardiol
@nl
P2093
P50
P356
P1476
2016 ESC Position Paper on can ...... mittee for Practice Guidelines
@en
2016 ESC Position Paper on can ...... he European Society of Cardiol
@en
P2093
Adam Torbicki
Alexander R Lyon
Alexander R. Lyon
Dania Mohty
Daniel J Lenihan
Daniel J. Lenihan
Daniel Rodriguez Muñoz
Gregory Y. H. Lip
Jose Luis Zamorano
Massimo F Piepoli
P304
P356
10.1093/EURHEARTJ/EHW211
P407
P577
2016-08-26T00:00:00Z
2016-09-21T00:00:00Z